Pharma Mar SA
Javier Jimenez is a seasoned medical executive currently serving as the Chief Medical Officer at PharmaMar since May 2024, where the focus is on leading the Clinical Department in the development of innovative marine-derived oncology therapies. Prior to this role, Javier held the position of Chief Medical Officer at Flatiron Health from June 2022 to May 2024, emphasizing data analysis and real-world data methodologies. Additional experience includes serving as Executive VP for Real World Evidence (RWE) and Late Phase at Syneos Health (February 2020 - June 2022), VP Global Head of RWE and Clinical Outcomes at Sanofi (January 2017 - January 2020), and VP of Medical Evidence and Observational Research at AstraZeneca (August 2013 - December 2016), where responsibilities included leading the Global Head of the Observational Research Center.
This person is not in any teams
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.